Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333031 · ClinicalTrials.gov registry record · Phase 1
A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies
A Phase 1 study, sponsored by Herbert Lyerly.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03333031 is a Phase 1 study that was terminated before completion, run by Herbert Lyerly. The registered enrollment target is 7 participants.
The verdict
NCT03333031, a Phase 1 study, was terminated before completion, sponsored by Herbert Lyerly.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for imaging. HS-196 can freely enter tumor cells to selectively bind Hsp90. Due to the the NIR dye, HS-196 accumulation in the malignant cells allows for specific visualization of tumors within the body.
Interventions
- DRUG HS-196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333031
The ClinicalTrials.gov registry entry for NCT03333031 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Herbert Lyerly, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HS-196 is the first listed.
NCT03333031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03333031 about?
NCT03333031 is a clinical study titled "A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies". HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for imaging. ...
What is the current status of trial NCT03333031?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-08-10. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT03333031?
The interventions under investigation include: HS-196 (DRUG).
Who is sponsoring clinical trial NCT03333031?
This trial is sponsored by Herbert Lyerly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.